TARA
Protara Therapeutics, Inc. NASDAQ Listed Oct 22, 2014$5.37
Mkt Cap $207.2M
52w Low $2.77
51.5% of range
52w High $7.82
50d MA $5.37
200d MA $5.06
P/E (TTM)
-4.0x
EV/EBITDA
-2.8x
P/B
1.2x
Debt/Equity
0.0x
ROE
-29.2%
P/FCF
-4.0x
RSI (14)
—
ATR (14)
—
Beta
1.50
50d MA
$5.37
200d MA
$5.06
Avg Volume
923.8K
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
345 Park Avenue South · New York City, NY 10010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 5.37 | -0.6% | -1.9% | — | — | — | — | — |
| May 7, 2026 | BMO | — | — | — | 5.66 | +0.0% | -5.1% | — | — | — | — | — |
| Mar 10, 2026 | AMC | -0.32 | -0.37 | -15.6% | 5.71 | -1.1% | -1.9% | -6.8% | -7.9% | -5.1% | -4.6% | — |
| Nov 10, 2025 | AMC | -0.39 | -0.31 | +20.5% | 4.53 | +1.1% | +18.3% | +17.0% | +16.3% | +21.6% | +23.0% | — |
| Aug 11, 2025 | AMC | -0.43 | -0.35 | +18.6% | 3.10 | +1.3% | -1.0% | +5.2% | +2.9% | -2.3% | +3.9% | — |
| May 8, 2025 | AMC | -0.47 | -0.29 | +38.3% | 3.37 | +0.0% | -3.9% | -3.0% | -4.5% | -7.1% | -7.7% | — |
| Mar 5, 2025 | AMC | -0.57 | -0.48 | +15.8% | 3.63 | +0.6% | +8.0% | +10.7% | +3.3% | +12.9% | +12.1% | — |
| Nov 12, 2024 | AMC | -0.50 | -0.50 | +0.0% | 2.58 | +1.2% | +4.3% | +0.0% | -4.3% | -10.5% | -10.1% | — |
| Aug 6, 2024 | AMC | -0.82 | -0.45 | +45.1% | 2.07 | +4.3% | -8.2% | -8.2% | -8.2% | -6.3% | -7.7% | — |
| May 2, 2024 | AMC | -0.99 | -0.97 | +2.0% | 2.89 | +0.7% | +0.7% | +0.3% | -0.7% | -2.1% | +3.1% | — |
| Mar 13, 2024 | AMC | -1.03 | -0.90 | +12.6% | 3.65 | +1.4% | -2.2% | +0.8% | +9.6% | +9.6% | +10.4% | — |
| Nov 3, 2023 | AMC | -1.10 | -0.87 | +20.9% | 1.35 | +4.4% | +1.5% | -11.9% | -11.9% | -11.9% | -11.9% | — |
| Aug 3, 2023 | AMC | -0.97 | -1.00 | -3.1% | 2.54 | +0.4% | -4.7% | -7.5% | -7.5% | -5.9% | -5.9% | — |
| May 4, 2023 | AMC | -1.00 | -0.80 | +20.0% | 3.05 | +0.0% | +1.0% | +1.3% | +2.0% | +6.9% | +11.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.48 | $6.41 | -1.1% | -0.6% | +0.0% | +0.8% | +0.5% | +1.1% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.22 | $6.72 | +8.0% | +9.3% | +10.5% | -10.3% | -8.0% | -7.7% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.75 | $6.38 | -5.5% | -0.6% | -4.6% | +7.6% | +9.2% | +12.0% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.32 | $4.09 | -5.3% | -18.5% | -21.3% | -19.0% | -19.9% | -17.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.65 | +0.6% | +8.0% | +10.7% | +3.3% | +12.9% | +12.1% |
| Dec 6 | Guggenheim | Maintains | Buy → Buy | — | $6.02 | $5.66 | -6.0% | -1.8% | +10.8% | +3.8% | +3.8% | +3.8% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.02 | $5.66 | -6.0% | -1.8% | +10.8% | +3.8% | +3.8% | +3.8% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.69 | $2.78 | +3.3% | -4.1% | -8.2% | -14.1% | -13.8% | -14.1% |
| Aug 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.90 | $1.91 | +0.5% | +2.1% | +0.5% | +4.2% | +7.9% | +5.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.96 | +3.2% | +0.0% | +0.0% | +2.1% | +0.5% | +4.2% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.91 | $2.88 | -1.0% | -0.3% | -1.4% | -2.7% | +2.4% | +3.1% |
| Apr 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.64 | $3.08 | +16.7% | +15.5% | +13.6% | +6.8% | +15.5% | +11.0% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.65 | +0.6% | -5.5% | -11.3% | -12.1% | -14.9% | -17.4% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.70 | +1.4% | -2.2% | +0.8% | +9.6% | +9.6% | +10.4% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.54 | $2.55 | +0.4% | -4.7% | -7.5% | -7.5% | -5.9% | -5.9% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.08 | $3.13 | +1.6% | +0.3% | +1.0% | +5.8% | +10.1% | +6.2% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.16 | $3.18 | +0.6% | -4.4% | -0.3% | -2.2% | -3.5% | -2.5% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.72 | $3.70 | -0.5% | -0.5% | -12.4% | -25.8% | -15.6% | -17.5% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.20 | $3.30 | +3.1% | +7.5% | +8.4% | +9.7% | +8.4% | +13.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.34 | +0.3% | -7.5% | -12.6% | -15.9% | -15.9% | -13.2% |
| Nov 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.14 | $7.29 | +2.1% | +6.0% | +8.7% | +5.5% | +3.5% | +2.8% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.26 | $10.01 | +8.1% | +10.0% | +7.1% | +6.6% | +13.5% | +8.7% |
| Nov 25 | Guggenheim | Maintains | Buy → Buy | — | $23.40 | $23.62 | +0.9% | +4.4% | -0.9% | +2.8% | -4.1% | -1.2% |
| Nov 25 | Cowen & Co. | Maintains | Outperform → Outperform | — | $23.40 | $23.62 | +0.9% | +4.4% | -0.9% | +2.8% | -4.1% | -1.2% |
| Oct 19 | Cowen & Co. | Maintains | Outperform → Outperform | — | $20.08 | $21.93 | +9.2% | +7.4% | +5.3% | +6.1% | +6.6% | +7.0% |
| Jul 29 | Guggenheim | Maintains | Buy → Buy | — | $27.45 | $28.88 | +5.2% | -6.7% | -6.1% | -9.1% | -8.7% | -4.3% |
| Jan 22 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $28.34 | $28.34 | +0.0% | +20.0% | +29.1% | +18.2% | +22.4% | +16.4% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Protara disclosed material information via Regulation FD, suggesting a significant announcement (likely clinical, partnership, or financial news) that could immediately impact stock valuation and trading behavior.
Mar 30
8-K
Unknown — 8-K Filing
Taravant's clinical progress and anticipated 2026 milestones suggest potential catalysts for value creation, but investors should await actual regulatory approvals or trial data before committing capital to this cash-burning biotech.
Mar 10
8-K · 8.01
!! High
Protara Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Protara Therapeutics presented clinical trial data for TARA-002 showing efficacy results in BCG-unresponsive and BCG-naïve bladder cancer patients, with preliminary response assessments completed across both patient populations.
Feb 24
Data updated apr 27, 2026 3:58am
· Source: massive.com